Other OTC - Delayed Quote USD

Nexeon Medsystems Inc (NXNN)

0.0001 0.0000 (0.00%)
At close: September 14 at 10:06 AM EDT
Loading Chart for NXNN
DELL
  • Previous Close 0.0001
  • Open 0.0001
  • Bid --
  • Ask --
  • Day's Range 0.0001 - 0.0001
  • 52 Week Range 0.0001 - 0.0001
  • Volume 265
  • Avg. Volume 0
  • Market Cap (intraday) 78,625
  • Beta (5Y Monthly) 7.19
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.

www.nexeonmedsystems.com

62

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: NXNN

Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NXNN
0.00%
S&P 500
5.06%

1-Year Return

NXNN
0.00%
S&P 500
20.71%

3-Year Return

NXNN
99.98%
S&P 500
19.73%

5-Year Return

NXNN
100.00%
S&P 500
72.77%

Compare To: NXNN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NXNN

Valuation Measures

As of 4/19/2024
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    0.01

  • Enterprise Value/EBITDA

    -0.18

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -16.84%

  • Return on Assets (ttm)

    -19.72%

  • Return on Equity (ttm)

    -17.39%

  • Revenue (ttm)

    9.82M

  • Net Income Avi to Common (ttm)

    -1.65M

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    125.57k

  • Total Debt/Equity (mrq)

    43.78%

  • Levered Free Cash Flow (ttm)

    1.57M

Research Analysis: NXNN

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS